Table 4.
Reproductive outcomes of studies reporting FST with conization for early-stage cervical cancer greater than 2 cm.
| De Vincenzo et al. [17] | Rendòn et al. [25] | Salihi et al. [27] | |
|---|---|---|---|
| Patients, n | 13 | 25 | 10 |
| Year | 2021 | 2020 | 2015 |
| Cervical cancer greater than 2 cm, n (%) | 13 (100) | 25 (100) | 5 (50) |
| Age, years (median) | 29 (23–36) | 27 (20–37) | 31.7 (25–36) |
| FST approach employed, n (%) | Cold-knife conization, 9 (69.2) | Conization, 5 (20) | Conization, 5 (50) |
| NACT, n (%) | 13 (100) | 25 (100) | 5 (100) |
| NACT regimen, n (%) | TP for 3 cycles, 13 (100) | Carboplatin + paclitaxel, 8 (32) TP, 7 (28) TIP, 4 (16) Paclitaxel + cisplatin + 5- fluorouracil, 3 (12) 5- fluorouracil + ifosfamide + cisplatin, 2 (8) Vincristine + bleomycin + cisplatin, 1 (4) |
TP or TP for 3 cycles, 1 (20) TC for 9 cycles, 4 (80) |
| Nulliparous, n (%) | 12 (92.3) | n.d. | 5 (100) |
| Primiparous, n (%) | 1 (7.7) | n.d. | 0 |
| Attempted to conceive, n (%) | 3 (33.3) | n.d. | 5 (100) |
| Follow-up period, months (mean or median) | 37 (18–76) | 47 (13–133) | 58 (13–122) |
| Pregnancies, n (%) | 2 (66.7) | 13 (56.5) | 1 (20) |
| Spontaneous pregnancies, n (%) | 2 (100) | n.d. | 1 (100) |
| Assisted reproductive technologies, n (%) | 0 | n.d. | 0 |
| Miscarriages, n (%) | 0 | 1 (7.7) | 0 |
| Ectopic pregnancies, n (%) | 0 | 0 | 0 |
| Twin pregnancy, n (%) | 0 | 0 | 0 |
| Preterm delivery, n (%) | 1 (50) | 7 (53.8) | 0 |
| Full-term delivery (%) | 1 (50) | 4 (30.8) | 1 (100) |
| Live births, n (%) | 2 (66.7) | 11 (84.6) 1 ongoing pregnancy |
1 (100) |
| PR (%) | 66.7 | 56.5 | 20 |
| MR (%) | 0 | 7.7 | 0 |
| LBR (%) | 66.7 | 84.6 | 100 |
FST: fertility-sparing treatment; NACT: neo-adjuvant chemotherapy; TIP: paclitaxel, ifosfamide and cisplatin; TP: paclitaxel and cisplatin; TC: paclitaxel and carboplatin; PR: pregnancy rate; MR: miscarriage rate; LBR: live birth rate.